These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 14583175)

  • 1. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.
    Abraira C; Duckworth W; McCarren M; Emanuele N; Arca D; Reda D; Henderson W;
    J Diabetes Complications; 2003; 17(6):314-22. PubMed ID: 14583175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
    Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
    Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.
    Emanuele N; Klein R; Abraira C; Colwell J; Comstock J; Henderson WG; Levin S; Nuttall F; Sawin C; Silbert C; Lee HS; Johnson-Nagel N
    Diabetes Care; 1996 Dec; 19(12):1375-81. PubMed ID: 8941467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM).
    Abraira C; Emanuele N; Colwell J; Henderson W; Comstock J; Levin S; Nuttall F; Sawin C
    Diabetes Care; 1992 Nov; 15(11):1560-71. PubMed ID: 1308130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes.
    Duckworth WC; McCarren M; Abraira C;
    Endocr Pract; 2006; 12 Suppl 1():85-8. PubMed ID: 16627388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report.
    Abraira C; Duckworth WC; Moritz T;
    Diabetes Obes Metab; 2009 Feb; 11(2):150-6. PubMed ID: 18671796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes.
    Abraira C; Colwell J; Nuttall F; Sawin CT; Henderson W; Comstock JP; Emanuele NV; Levin SR; Pacold I; Lee HS
    Arch Intern Med; 1997 Jan; 157(2):181-8. PubMed ID: 9009975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic memory: Evolving concepts.
    Misra A; Bloomgarden Z
    J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM).
    Pitale SU; Abraira C; Emanuele NV; McCarren M; Henderson WG; Pacold I; Bushnell D; Colwell JA; Nuttall FQ; Levin SR; Sawin CT; Comstock JP; Silbert CK
    Diabetes Care; 2000 Sep; 23(9):1316-20. PubMed ID: 10977025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
    Dziuba J; Alperin P; Racketa J; Iloeje U; Goswami D; Hardy E; Perlstein I; Grossman HL; Cohen M
    Diabetes Obes Metab; 2014 Jul; 16(7):628-35. PubMed ID: 24443793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose control and vascular complications in veterans with type 2 diabetes.
    Duckworth W; Abraira C; Moritz T; Reda D; Emanuele N; Reaven PD; Zieve FJ; Marks J; Davis SN; Hayward R; Warren SR; Goldman S; McCarren M; Vitek ME; Henderson WG; Huang GD;
    N Engl J Med; 2009 Jan; 360(2):129-39. PubMed ID: 19092145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fasting Glucose Variation Predicts Microvascular Risk in ACCORD and VADT.
    Zhou JJ; Koska J; Bahn G; Reaven P
    J Clin Endocrinol Metab; 2021 Mar; 106(4):1150-1162. PubMed ID: 33367811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
    Meier M; Hummel M
    Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of PAI-1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT).
    Azad N; Agrawal L; Emanuele NV; Klein R; Bahn GD; McCarren M; Reaven P; Hayward R; Duckworth W;
    Diabetes Care; 2014 Feb; 37(2):501-6. PubMed ID: 24101699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of the veteran affairs diabetes trial: Lessons learned.
    Tran K; Reaven P
    Rev Endocr Metab Disord; 2020 Dec; 21(4):537-546. PubMed ID: 32458291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive glycemic control and cardiovascular disease: an update.
    Brown A; Reynolds LR; Bruemmer D
    Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial.
    Saremi A; Schwenke DC; Bahn G; Ge L; Emanuele N; Reaven PD;
    Metabolism; 2015 Feb; 64(2):218-25. PubMed ID: 25456099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial.
    Florez H; Reaven PD; Bahn G; Moritz T; Warren S; Marks J; Reda D; Duckworth W; Abraira C; Hayward R; Emanuele N;
    Diabetes Obes Metab; 2015 Oct; 17(10):949-55. PubMed ID: 25964070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.